Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Learn more about:
Related Clinical Trial
Molecular Epidemiology of Pediatric Germ Cell Tumors Multidisciplinary Approach to Fatigue A Study of DS-9606a in Patients With Advanced Solid Tumors Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Hepatocellular Carcinoma A Phase II Trial Evaluating the Efficacy of Cabozantinib With Patients With Refractory GCTs Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors A Study of a New Way to Treat Children With a Brain Tumor Called NGGCT Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Symptom Management for YA Cancer Survivors A Study of miRNA 371 in Patients With Germ Cell Tumors Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors Aflac ST0901 CHOANOME – Sirolimus in Solid Tumors Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) A Pilot RCT of the PRISM Intervention for AYAs With Cancer Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Molecular-Guided Therapy for Childhood Cancer EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Busulfan in Treating Children and Adolescents With Refractory CNS Cancer CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven’t Responded to Therapy ABT-751 in Treating Young Patients With Refractory Solid Tumors Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Collecting and Storing Tissue From Young Patients With Cancer Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Everolimus in Refractory Testicular Germ Cell Cancer Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS) A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors First Line TIP in Poor Prognosis TGCTs. Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma Disulfiram and Cisplatin in Refractory TGCTs. Role of Axumin PET Scan in Germ Cell Tumor Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors Study Evaluating the Impact of Short Message Service on Compliance With Surveillance of Patients With Germ-cell Tumors Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01 Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors Accelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors Germ Cell Tumor and Testicular Tumor DNA Registry A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors

Brief Title

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Official Title

A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy

Brief Summary

      Toxicities related to pediatric cancer treatment can lead to significant illness, organ
      damage, treatment delays, increased health care cost, and decrease in quality of life. Such
      toxicities are largely due to tissue damage sustained by chemotherapy, and strategies
      designed to limit such cellular damage to normal tissues may reduce therapy-related morbidity
      and mortality. In addition to their in vitro and in vivo anti-cancer effects, naturally
      occurring soy isoflavones have anti-inflammatory and anti-oxidant properties, and have been
      shown to reduce side effects of therapy in adult oncology clinical trials. This study will
      examine the effect of genistein, the major isoflavone component in soybeans and the most
      extensively studied of the soy isoflavones, on short-term side effects of myelosuppressive
      chemotherapy in pediatric cancer patients. Subjects will be randomized to receive either: a)
      30 mg genistein daily throughout chemotherapy Cycles 1 and 2 and placebo during chemotherapy
      Cycles 3 and 4; or b) placebo daily during chemotherapy Cycles 1 and 2 and 30 mg genistein
      daily during chemotherapy Cycles 3 and 4. Investigators hypothesize that subjects will have
      fewer short-term therapy-related side effects during cycles of chemotherapy given in
      conjunction with genistein supplementation than cycles given with placebo.

Detailed Description

      This is a multi-center, randomized, double blind, placebo-controlled crossover study to
      evaluate the effect of soy isoflavones on the short term untoward effects of myelosuppressive
      chemotherapy used to treat pediatric cancers. Newly diagnosed cancer patients aged 1-21 years
      will be registered to the study and informed consent will be obtained prior to any
      study-related procedures. Stratification will be based on length of chemotherapy cycles,
      between 14 day and 21 day cycles. Within strata registered subjects will be randomized 1:1 to
      one of two schedules:

      Arm A: Subjects will receive genistein daily throughout chemotherapy cycles 1 and 2, and
      placebo during chemotherapy cycles 3 and 4

      Arm B: Subjects will receive placebo daily throughout chemotherapy cycles 1 and 2, and
      genistein during chemotherapy cycles 3 and 4

      Subjects will be assessed for safety and efficacy during each cycle with clinical labs,
      cytokine panels, and physical exams. Drug compliance will be monitored by use of a patient
      diary as well as monitoring of serum genistein levels. Adverse events will be monitored
      starting on Cycle 1 Day 1 through 30 days following the last day of protocol therapy

Study Phase

Phase 2

Study Type


Primary Outcome

Time to neutrophil count recovery following myelosuppressive chemotherapy

Secondary Outcome

 Serum marker levels of inflammation during cycles of chemotherapy





Study Arms / Comparison Groups

 Arm A: Genistein followed by Placebo
Description:  Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

August 2016

Completion Date

September 2021

Primary Completion Date

September 2021

Eligibility Criteria

        Inclusion Criteria

          1. Newly diagnosed solid tumor or lymphoma with histological verification

          2. Age 1 - 21 years at time of diagnosis

          3. Karnofsky/Lanksy performance score of ≥ 50

          4. Able to tolerate enteral medication administration

          5. Planned chemotherapeutic regimen for a patient must meet all of the following

               -  A known myelosuppressive regimen which includes at least two of the following
                  agents: actinomycin, carboplatin, cisplatin, cyclophosphamide, daunorubicin,
                  doxorubicin, etoposide, ifosfamide, topotecan

               -  At least four consecutive cycles

               -  Cycle length is either 14 or 21 days

               -  Regimen must either alternate myelosuppressive chemotherapeutic agents in an
                  X-Y-X-Y format, such that the same chemotherapy is given every other cycle (e.g.
                  vincristine/doxorubicin/cyclophosphamide │ ifosfamide/etoposide), or repeat the
                  same chemotherapeutic agents each cycle in an X-X-X-X format (e.g. repeated
                  cycles of cisplatin/etoposide/bleomycin). Courses eligible for this trial may
                  occur at any time during treatment provided that they are consecutive and follow
                  the one of the described patterns. Non-myelosuppressive anti-neoplastic
                  treatments will not be considered for the purposes of determining eligibility.
                  Questions regarding whether or not a patient's chemotherapy plan meets inclusion
                  criteria will be decided by the Study Chair.

          6. Informed consent or parental permission and assent obtained prior to trial-related

          7. Able and willing to comply with all study related procedures

          8. Women of childbearing potential must agree to use adequate contraception prior to
             study entry and for the duration of study participation. Should a woman become
             pregnant or suspect she is pregnant while participating in this study, she should
             inform her treating physician immediately

        Exclusion Criteria

          1. Known allergy to soy or any soy-based food or supplement

          2. Unable or unwilling to discontinue consuming prohibited soy-based food or supplements
             while participating in this study

          3. Pre-existing neutropenia or neutrophil qualitative or quantitative disorder

          4. Pre-existing cytopenia or bone marrow failure syndrome

          5. History of gastric or duodenal ulcers or hyperacidity syndromes

          6. History of Human Immunodeficiency Virus (HIV)

          7. Has an active infection requiring systemic therapy

          8. Planned treatment does not include myelosuppressive chemotherapy

          9. Enrolled on a therapeutic or supportive care clinical trial within the last 30 days

         10. Current acute or chronic leukemia diagnosis

         11. Requires medication dosing via an enteral feeding tube that terminates in the duodenum
             or jejunum. (Enteral feeding tubes that terminate in the stomach are acceptable for
             study medication delivery.)

         12. Pregnant or breastfeeding woman

         13. Incarceration

         14. Secondary malignancy, i.e. the cancer for which the patient is presently or will be
             receiving treatment may not be a malignancy related to prior cancer therapy

         15. Any condition which might be worsened by estrogen, such as breast cancer, uterine
             cancer, ovarian cancer, endometriosis or uterine fibroids

         16. Any condition, in the investigator's opinion, that would compromise patient safety or
             study outcomes

         17. Anyone who, in the investigator's discretion, would be unwilling or unable to comply
             with study procedures




1 Year - 21 Years

Accepts Healthy Volunteers



William C. Petersen, Jr., M.D., , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

University of Virginia

Study Sponsor

William C. Petersen, Jr., M.D., Principal Investigator, University of Virginia

Verification Date

February 2022